Porter's Five Forces: HER2 Borderline Resolver: Multi-Omics Reflex Test for Equivocal Breast Biopsies
A reflex multi-omics test for breast biopsies with equivocal HER2 results, integrating genomic, proteomic, and transcriptomic readouts from one FFPE block to give a clear HER2-driver call that decides trastuzumab/pertuzumab eligibility.
The analysis reveals a high-barrier entry environment where the primary threat is not direct competition, but the inertia of established IHC/FISH workflows and the power of large diagnostic labs. While the technical moat is strong due to multi-omic integration, the commercial success depends on navigating the high bargaining power of payers and the dominance of a few large-scale pathology providers.
medium
Threat of New Entrants3
medium
Threat of Substitutes2
medium
Competitive Rivalry2
high
Bargaining Power of Buyers2
medium
Bargaining Power of Suppliers2
Necessary to analyze the competitive landscape of established pathology giants like Roche and Quest Diagnostics who control the current testing workflows. · Generated 2026-10-17 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated